The latest clinical findings of Igrelimogene litadenorepvec were unveiled at the 2023 ESMO_IO, demonstrating its potential benefit and setting the stage for subsequent investigations.

The latest 4-year follow-up data from C-144-01 on lifileucel’s treatment outcomes and patterns of response were reported in 2023 ESMO_IO.

On 2 Dec 2023, the latest clinical trial about TQB2450 for the treatment for patients with hepatocellular carcinoma at high risk of recurrence was presented in 2023 ESMO_ASIA.

the latest clinical results of Anlotinib Dihydrochloride were presented in 2023 ESMO_ASIA.

On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment of head and neck squamous cell cancer (HNSCC) was reported in 2023 ESMO_ASIA.

On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.

Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3-mediated NRG1 signaling in NRG1+ cancer.

On Dec 2, 2023, results from a Penpulimab-based neoadjuvant/adjuvant therapy trial for resectable advanced non-small cell lung cancer were presented at ESMO_ASIA 2023.

At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.

TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations.

On 2 Dec 2023, the updated results of these two studies with extended follow-up were presented in 2023 ESMO_ASIA.

On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment on non-small cell lung cancer was reported in 2023 ESMO_ASIA.